Tiazofurin (Synonyms: 噻唑呋林; NSC 286193; Riboxamide)

目录号: HY-114570 纯度: 99.84%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Tiazofurin (NSC 286193) 是一种具有抗肿瘤活性的合成核苷类似物。Tiazofurin 在细胞内被代谢为噻唑-4-羧酰胺腺苷二核苷酸 (TAD)，这是一种强效的 IMP 脱氢酶 (IMPDH) 抑制剂。Tiazofurin 增强 K562 细胞中 IL-6 的自体分泌。Tiazofurin 还具有抗正痘病毒 (orthopoxvirus) 和抗天花病毒活性。Tiazofurin 可用于白血病和肺癌研究

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tiazofurin Chemical Structure

CAS No. : 60084-10-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥450	In-stock
5 mg	￥900	In-stock
10 mg	￥1500	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

•Nat Commun. 2025 Mar 18;16(1):2641. [Abstract]

Tiazofurin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Tiazofurin (NSC 286193) is a synthetic nucleoside analogue with antineoplastic activity. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH). Tiazofurin enhances the autosecretion of IL-6 in K562 cells. Tiazofurin also has anti-orthopoxvirus and anti-variola activities. Tiazofurin can be used for the study of leukemia and lung cancer^[1]^[2]^[3]^[4].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
5637	IC₅₀	24 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line	[PMID: 9171883]
ACHN	IC₅₀	> 100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma	[PMID: 9171883]
B16	IC₅₀	16.2 μM Compound: 1 (tiazofurin)	Inhibitory concentration against B16 melanoma cell lines Inhibitory concentration against B16 melanoma cell lines	[PMID: 7562914]
B16	IC₅₀	16.2 μM Compound: tiazofurin	In vitro inhibitory activity against B16 murine melanoma cells In vitro inhibitory activity against B16 murine melanoma cells	[PMID: 2120442]
CCRF-CEM	IC₅₀	10 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-CEM, human acute T-lymphoblastic leukemia	[PMID: 9171883]
CCRF-SB	IC₅₀	7.5 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia Compound was tested for antiproliferative activity against CCRF-SB, human acute B-lymphoblastic leukemia	[PMID: 9171883]
CHO-K1	IC₅₀	6.4 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary cells Compound was tested for antiproliferative activity against CHO-K1, Chinese hamster ovary cells	[PMID: 9171883]
HL-60	IC₅₀	0.19 μM Compound: 1	Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HL-60	IC₅₀	0.19 μM Compound: 1, Tiazofurin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23010263]
HL-60	IC₅₀	0.19 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 26859071]
HL-60	IC₅₀	1.84 μM Compound: 1, tiazofurin	Cytotoxicity against human HL60 cell line after 48 hrs by MTT assay Cytotoxicity against human HL60 cell line after 48 hrs by MTT assay	[PMID: 17543526]
HL-60	IC₅₀	2.5 μM Compound: 1 (tiazofurin)	Inhibitory concentration range against human HL-60 cell line Inhibitory concentration range against human HL-60 cell line	[PMID: 7562914]
HL-60	IC₅₀	6.1 μM Compound: tiazofurin	In vitro inhibitory activity against HL-60 human promyelocytic leukemia cells In vitro inhibitory activity against HL-60 human promyelocytic leukemia cells	[PMID: 2120442]
HL-60	IC₅₀	8.7 μM Compound: 1 (tiazofurin)	Inhibitory concentration against HL-60 human promyelocytic leukemia Inhibitory concentration against HL-60 human promyelocytic leukemia	[PMID: 7562914]
HL-60	IC₅₀	9.32 μM Compound: 1	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16495053]
HL-60	IC₅₀	9.32 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit HL-60 cell growth Concentration required to inhibit HL-60 cell growth	[PMID: 12951086]
HT-29	IC₅₀	0.26 μM Compound: 1	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HT-29	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 23010263]
HT-29	IC₅₀	0.26 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26859071]
HT-29	IC₅₀	0.89 μM Compound: 1, tiazofurin	Cytotoxicity against human HT29 cell line after 48 hrs by MTT assay Cytotoxicity against human HT29 cell line after 48 hrs by MTT assay	[PMID: 17543526]
HT-29	IC₅₀	1.01 μM Compound: 1	Antiproliferative activity against human HT29 cell line Antiproliferative activity against human HT29 cell line	[PMID: 16495053]
HT-29	IC₅₀	1.01 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit HT-29 cell growth Concentration required to inhibit HT-29 cell growth	[PMID: 12951086]
HT-29	IC₅₀	1.01 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against HT29 cells after 24 hrs by MTT assay Cytotoxicity against HT29 cells after 24 hrs by MTT assay	[PMID: 16908146]
HT-29	IC₅₀	100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma Compound was tested for antiproliferative activity against HT29, human colon adenocarcinoma	[PMID: 9171883]
HeLa	IC₅₀	100 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma Compound was tested for antiproliferative activity against HeLa, human cervix carcinoma	[PMID: 9171883]
HeLa	IC₅₀	3.82 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HeLa	IC₅₀	3.82 μM Compound: 1, Tiazofurin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23010263]
HeLa	IC₅₀	3.82 μM Compound: 1; Tiazofurin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26859071]
HeLa	IC₅₀	4.76 μM Compound: 1	Antiproliferative activity against human HeLa cell line Antiproliferative activity against human HeLa cell line	[PMID: 16495053]
HeLa	IC₅₀	4.76 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against HeLa cells after 24 hrs by MTT assay Cytotoxicity against HeLa cells after 24 hrs by MTT assay	[PMID: 16908146]
Jurkat	IC₅₀	0.04 μM Compound: 1	Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Jurkat	IC₅₀	0.04 μM Compound: 1, Tiazofurin	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 23010263]
Jurkat	IC₅₀	0.04 μM Compound: 1; Tiazofurin	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 26859071]
Jurkat	IC₅₀	0.14 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against Jurkat cells after 24 hrs by MTT assay Cytotoxicity against Jurkat cells after 24 hrs by MTT assay	[PMID: 16908146]
Jurkat	IC₅₀	0.51 μM Compound: 1, tiazofurin	Cytotoxicity against human Jurkat T cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 48 hrs by MTT assay	[PMID: 17543526]
K562	IC₅₀	1.89 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
K562	IC₅₀	1.89 μM Compound: 1; Tiazofurin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 26859071]
K562	IC₅₀	2.09 μM Compound: 1, Tiazofurin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 23010263]
K562	IC₅₀	2.5 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against K562, human erythroid leukemia Compound was tested for antiproliferative activity against K562, human erythroid leukemia	[PMID: 9171883]
K562	IC₅₀	2.98 μM Compound: 1, tiazofurin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 17543526]
K562	IC₅₀	3 μM Compound: 1, TR	Concentration of the Antiproliferative compound required for the 50% inhibition of Growth against K562 cells Concentration of the Antiproliferative compound required for the 50% inhibition of Growth against K562 cells	[PMID: 11806722]
K562	IC₅₀	3 μM Compound: TF (1)	Antiproliferative activity against K562 erythroid leukemic cells was determined. Antiproliferative activity against K562 erythroid leukemic cells was determined.	[PMID: 9258359]
K562	IC₅₀	3 μM Compound: TR	Tested for inhibition of growth in human erythroleukemia K-562 cells. Tested for inhibition of growth in human erythroleukemia K-562 cells.	[PMID: 9111303]
K562	IC₅₀	4.16 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit K562 cell growth Concentration required to inhibit K562 cell growth	[PMID: 12951086]
K562	IC₅₀	4.5 μM Compound: 1 (tiazofurin)	Inhibitory concentration against K562 human myelogenous leukemia cell line Inhibitory concentration against K562 human myelogenous leukemia cell line	[PMID: 7562914]
K562	IC₅₀	5.29 μM Compound: 1	Antiproliferative activity against human K562 cell line Antiproliferative activity against human K562 cell line	[PMID: 16495053]
K562	IC₅₀	5.29 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 16908146]
L1210	IC₅₀	2.9 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia Compound was tested for antiproliferative activity against L1210, murine lymphocytic leukemia	[PMID: 9171883]
L1210	IC₅₀	6.2 μM Compound: tiazofurin	In vitro inhibitory activity against L1210 murine lymphocytic leukemia cells In vitro inhibitory activity against L1210 murine lymphocytic leukemia cells	[PMID: 2120442]
L1210	IC₅₀	7.4 μM Compound: 1 (tiazofurin)	Inhibitory concentration against L1210 murine lymphocytic leukemia Inhibitory concentration against L1210 murine lymphocytic leukemia	[PMID: 7562914]
LoVo	IC₅₀	> 128 μM Compound: 1 (tiazofurin)	Inhibitory concentration against LoVo human colon adenocarcinoma cell lines Inhibitory concentration against LoVo human colon adenocarcinoma cell lines	[PMID: 7562914]
MCF7	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23010263]
MCF7	IC₅₀	1.78 μM Compound: 1; Tiazofurin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26859071]
MCF7	IC₅₀	6.39 μM Compound: 1, tiazofurin	Cytotoxicity against human MCF7 cell line after 48 hrs by MTT assay Cytotoxicity against human MCF7 cell line after 48 hrs by MTT assay	[PMID: 17543526]
MCF7	IC₅₀	7.98 μM Compound: 1	Antiproliferative activity against human MCF7 cell line Antiproliferative activity against human MCF7 cell line	[PMID: 16495053]
MCF7	IC₅₀	8.49 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit MCF-7 cell growth Concentration required to inhibit MCF-7 cell growth	[PMID: 12951086]
MDA-MB-231	IC₅₀	0.26 μM Compound: 1, Tiazofurin	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23010263]
MOLT-4	IC₅₀	5.2 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia Compound was tested for antiproliferative activity against MOLT-4, human acute T-lymphoblastic leukemia	[PMID: 9171883]
MRC5	IC₅₀	0.36 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31557614]
MRC5	IC₅₀	0.36 μM Compound: 1, Tiazofurin	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 23010263]
MRC5	IC₅₀	0.36 μM Compound: 1; Tiazofurin	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 26859071]
MRC5	IC₅₀	0.49 μM Compound: 1, tiazofurin	Cytotoxicity against human MRC5 cell line after 48 hrs by MTT assay Cytotoxicity against human MRC5 cell line after 48 hrs by MTT assay	[PMID: 17543526]
MRC5	IC₅₀	0.85 μM Compound: 1	Antiproliferative activity against human MRC5 cell line Antiproliferative activity against human MRC5 cell line	[PMID: 16495053]
MRC5	IC₅₀	0.85 μM Compound: 1 (Tiazofurin)	Concentration required to inhibit MRC-5 cell growth Concentration required to inhibit MRC-5 cell growth	[PMID: 12951086]
MRC5	IC₅₀	0.85 μM Compound: 1, NSC-286193, Tiazofurin	Cytotoxicity against MRC5 cells after 24 hrs by MTT assay Cytotoxicity against MRC5 cells after 24 hrs by MTT assay	[PMID: 16908146]
P388	IC₅₀	16.7 μM Compound: tiazofurin	In vitro inhibitory activity against P388 murine lymphocytic leukemia cells In vitro inhibitory activity against P388 murine lymphocytic leukemia cells	[PMID: 2120442]
P388	IC₅₀	2.2 μM Compound: 1 (tiazofurin)	Inhibitory concentration against P388 murine lymphocytic leukemia cell lines Inhibitory concentration against P388 murine lymphocytic leukemia cell lines	[PMID: 7562914]
Raji	IC₅₀	16.06 μM Compound: 1, tiazofurin	Cytotoxicity against human Raji cells after 48 hrs by MTT assay Cytotoxicity against human Raji cells after 48 hrs by MTT assay	[PMID: 17543526]
Raji	IC₅₀	5.28 μM Compound: 1	Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Raji	IC₅₀	5.28 μM Compound: 1, Tiazofurin	Cytotoxicity against human Raji cells after 72 hrs by MTT assay Cytotoxicity against human Raji cells after 72 hrs by MTT assay	[PMID: 23010263]
Raji	IC₅₀	5.28 μM Compound: 1; Tiazofurin	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 26859071]
Raji	IC₅₀	8.2 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma Compound was tested for antiproliferative activity against Raji, human Burkitt lymphoma	[PMID: 9171883]
WIL2-NS	IC₅₀	5.7 μM Compound: Tiazofurin	Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells Compound was tested for antiproliferative activity against Wil2-NS, human splenic lymphoblastoid cells	[PMID: 9171883]

体外研究
(In Vitro)

Tiazofurin (10 μM, 0-3 天) 影响 K562 人白血病细胞的生长动力学并促进红系分化，同时显著增加苯胺啶阳性细胞的百分比并提高糖蛋白 A (GpA) 的表达^[1]。
Tiazofurin (10 μM, 2 天) 增强 K562 细胞中 IL-6 的自体分泌^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Tiazofurin (200-700 mg/kg，腹腔注射，每日一次，第 1-9 天) 在敏感的小鼠移植肿瘤模型 (CDF1 小鼠中的 P388/L1210 白血病，B6C3F1 小鼠中的 Lewis 肺癌) 中发挥显著的抗肿瘤疗效^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	leukemia cells (P388/L1210) and Lewis lung carcinoma cells were intravenously inoculated into B6C3F1 mice or CDF1 mice^[2]
Dosage:	200, 700 mg/kg
Administration:	i.p., qd days 1-9
Result:	Exerted significant anti-tumor efficacy in sensitive murine transplanted tumor models (P388/L1210 leukemia in CDF1 mice, Lewis lung carcinoma in B6C3F1 mice).

分子量

260.27

Formula

C₉H₁₂N₂O₅S

CAS 号

60084-10-8

性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 125 mg/mL (480.27 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.8422 mL	19.2108 mL	38.4216 mL
5 mM	0.7684 mL	3.8422 mL	7.6843 mL
10 mM	0.3842 mL	1.9211 mL	3.8422 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.84%

选择批次：

Data Sheet (619 KB) SDS (393 KB)

COA (286 KB) HNMR (273 KB) RP-HPLC (238 KB) MS (69 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Talley CJ, et al. Tiazofurin-induced autosecretion of IL-6 and hemoglobin production in K562 human leukemia cells. Am J Hematol. 1997 Apr;54(4):301-5. [Content Brief]

[2]. Ahluwalia GS, et al. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol. 1984 Apr 15;33(8):1195-203. [Content Brief]

[3]. Tricot G, Jayaram HN, Weber G, Hoffman R. Tiazofurin: biological effects and clinical uses. Int J Cell Cloning. 1990;8(3):161-170. [Content Brief]

[4]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]

Tiazofurin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.8422 mL	19.2108 mL	38.4216 mL	96.0541 mL
	5 mM	0.7684 mL	3.8422 mL	7.6843 mL	19.2108 mL
	10 mM	0.3842 mL	1.9211 mL	3.8422 mL	9.6054 mL
	15 mM	0.2561 mL	1.2807 mL	2.5614 mL	6.4036 mL
	20 mM	0.1921 mL	0.9605 mL	1.9211 mL	4.8027 mL
	25 mM	0.1537 mL	0.7684 mL	1.5369 mL	3.8422 mL
	30 mM	0.1281 mL	0.6404 mL	1.2807 mL	3.2018 mL
	40 mM	0.0961 mL	0.4803 mL	0.9605 mL	2.4014 mL
	50 mM	0.0768 mL	0.3842 mL	0.7684 mL	1.9211 mL
	60 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6009 mL
	80 mM	0.0480 mL	0.2401 mL	0.4803 mL	1.2007 mL
	100 mM	0.0384 mL	0.1921 mL	0.3842 mL	0.9605 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tiazofurin60084-10-8NSC 286193 RiboxamideNSC286193NSC-286193Nucleoside Antimetabolite/AnalogOrthopoxvirusLeukemialung cancerIMPDHInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Tiazofurin (Synonyms: 噻唑呋林; NSC 286193; Riboxamide)

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

Tiazofurin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Tiazofurin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Tiazofurin (Synonyms: 噻唑呋林; NSC 286193; Riboxamide)

Customer Review

Tiazofurin 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

Tiazofurin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Tiazofurin 相关抗体:

摩尔计算器

稀释计算器

Tiazofurin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z